ACP
ALGS icon

Acuta Capital Partners’s Aligos Therapeutics ALGS Stock Holding History

Acuta Capital Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,570
Closed -$4.37M – 48
2021
Q2 		$4.37M Buy
+8,570
New +$5.46M 1.75% 19

Other funds holding ALGS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acuta Capital Partners's ALGS Position: Q3 2021 in Review

Acuta Capital Partners sold out of Aligos Therapeutics (ALGS) in Q3 2021, closing a stake of 8,570 shares — an estimated $4.37M sold.

Acuta Capital Partners first reported a position in ALGS in Q2 2021 and held it in 1 quarter. The position peaked at $4.37M in Q2 2021. 68 funds tracked by Wall St. Rank hold ALGS as of Q3 2021.

  • Acuta Capital Partners reported no remaining Aligos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 8,570 Aligos Therapeutics shares in Q3 2021, an estimated $4.37M.
  • Acuta Capital Partners first reported a position in Aligos Therapeutics in Q2 2021 and held it in 1 quarter.
  • Acuta Capital Partners's Aligos Therapeutics position peaked at $4.37M in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2021.

Based on Acuta Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.